Preclinical Models of Multiple Sclerosis: Advantages and Limitations Towards Better Therapies

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Multiple sclerosis (MS) is a central nervous system (CNS) disease with complex pathophysiology including inflammation, demyelination, and axonal injury.
• The unknown etiology and lack of naturally occurring animal models complicate preclinical studies for MS.
• Existing experimental models have limitations in fully recapitulating MS hallmarks.

Purpose of the Study:

• To review and critically evaluate current in vivo models used for studying multiple sclerosis (MS).
• To assess the potential of each model in mimicking MS and translating findings to patient therapies.
• To explore the role of new genomic technologies in improving existing MS models.

Main Methods:

• Review of established experimental autoimmune encephalomyelitis (EAE) model.
• Characterization of alternative CNS demyelination models (viral infection, neurotoxin administration).
• Discussion of the strengths and limitations of each model in relation to MS pathology.

Main Results:

• Experimental autoimmune encephalomyelitis (EAE) is widely used but does not capture all MS features.
• Viral and neurotoxin-induced models offer insights into immune function but have limitations in MS relevance.
• The distance of these models from natural MS can lead to misinterpretation of data.

Conclusions:

• No single experimental model perfectly replicates MS, necessitating careful interpretation of results.
• Each model provides valuable, albeit imperfect, insights into neuroinflammation and demyelination.
• Genomic technologies hold promise for enhancing the accuracy and translatability of MS preclinical models.